Table 1.
Characteristics of Solid Organ Transplant Recipients With Noninfluenza Respiratory Virus Infections
| Patient Characteristics | ADV (n = 38) | PIV (n = 113) | RSV (n = 104) | Total (n = 255) |
|---|---|---|---|---|
| Median time (IQR) from transplant to NI-RVI, mo | 10.8 (2–10.8) | 17.8 (6.5–31.6) | 19.7 (6.3–37.3) | 18.4 (5.9–35) |
| Demographics | ||||
| Age, median (IQR), y | 56.5 (45–65) | 57 (45–65) | 58 (49–65) | 57 (46–65) |
| Men | 50 (19) | 61 (69) | 64 (67) | 61 (155) |
| Organ transplanted | ||||
| Lung | 87 (33) | 78 (88) | 75 (78) | 78 (199) |
| Kidney | 3 (1) | 5 (6) | 6 (6) | 5 (13) |
| Liver | 0 (0) | 4 (4) | 9 (9) | 5 (13) |
| Heart | 3 (1) | 5 (6) | 6 (6) | 5 (13) |
| Small bowel | 0 (0) | 2 (2) | 1 (1) | 1 (3) |
| Kidney-pancreas | 3 (1) | 0 | 1 (1) | 1 (2) |
| Multiple | 5 (2) | 6 (7) | 3 (3) | 5 (12) |
| Immunosuppression at the time of NI-RVI | ||||
| Cyclosporine | 21 (8) | 20 (23) | 23 (24) | 21 (54) |
| Tacrolimus | 74 (28) | 80 (91) | 75 (78) | 77 (197) |
| Sirolimus/everolimus | 5 (2) | 18 (21) | 21 (22) | 17 (44) |
| Azathioprine | 5 (2) | 11 (13) | 10 (11) | 10 (26) |
| Mycophenolate mofetil | 79 (30) | 65 (74) | 62 (65) | 66 (169) |
| Belatacepta | 10 (4) | 2 (2) | 0 (0) | 2 (6) |
| Steroids | 92 (35) | 92 (104) | 84 (87) | 89 (226) |
| Alemtuzumab/antithymocyte globulin/rituximab within 3 mo of NI-RVI | 16 (6) | 9 (10) | 8 (8) | 9 (24) |
| Basiliximab within 3 mo of NI-RVI | 0 | 2 (2) | 6 (6) | 3 (8) |
| Acute rejection requiring bolus steroids within 3 mo before NI-RVIb | 29 (11) | 23 (26) | 12 (12) | 19 (49) |
| Acute rejection requiring bolus steroids within 1 mo before NI-RVI | 10 (4) | 12 (13) | 10 (11) | 11 (28) |
| Clinical characteristics at the time of NI-RVI | ||||
| ESRD on RRT | 5 (2) | 7 (8) | 13 (14) | 9 (24) |
| CMV infectionc | 16 (6) | 1 (1) | 10 (10) | 7 (17) |
| Lung involvement (pneumonia) | 24 (9) | 29 (33) | 24 (25) | 26 (67) |
| Hospital admission | 66 (25) | 54 (61) | 59 (61) | 58 (147) |
| Median inpatient length of stay (range), d | 16 (2–114) | 8 (1–150) | 7 (1–371) | 8 (1–371) |
Data are presented as % (No.) unless otherwise indicated. There were only 3 patients with neutropenia in our cohort, with absolute neutrophil counts of 920, 1150, and 1320/mm3 at the time of NI-RVI diagnosis.
Abbreviations: ADV, adenovirus; CMV, cytomegalovirus; ESRD, end-stage renal disease; IQR, interquartile range; NI-RVIs, noninfluenza respiratory virus infections; PIV, parainfluenza virus; RRT, renal replacement therapy; RSV, respiratory syncytial virus.
P = .003; 10% (4/38) of patients with ADV vs 1% (2/217) with RVP due to PIV or RSV infections received belatacept before RVI (P = .005).
P = .02; 92% (139/151) of patients with either ADV or PIV infections had received corticosteroid at the time of NI-RVI diagnosis vs those with RSV infection (P = .04).
P = .001; 16% (6/38) of patients with ADV vs 5% (11/217) with RVP due to PIV or RSV infections had CMV infection within 30 days before NI-RVI (P = .03).